Anti-estrogen and immune modulator combinations for treating breast cancer
Compositions for treating cancers of mucosal tissues including breast, prostate, ovary, colon are disclosed which include various combinations of new or conventional anti-estrogen compounds, aromatase inhibitors, immune modulators, immune inhibitors, immune inhibitor mimicking compounds and steroid or thyroid hormones. Methods of predicting susceptibility of a cancer of mucosal origin to treatment with a composition containing an immune inhibitor or an immune inhibitor mimicking compound are also disclosed. Preferred methods include identifying in a specimen of cancer cells the presence of a Poly-Ig (Fc) receptor or Poly-Ig-like (Fc) receptor capable of binding to an immune inhibitor or an immune inhibitor mimicking compound and of mediating immune inhibition of cancer cell growth.
1. A method of predicting susceptibility of a cancer patient to treatment with Tamoxifen, comprising:
detecting the presence of a Poly-Ig receptor, or the (Fc) region thereof, in a sample from the cancer patient, wherein the detection of a Poly-Ig receptor, or the (Fc) region thereof, is indicative of said cancer patient being more susceptible to treatment with Tamoxifen as compared to a sample obtained from a second patient, wherein said sample from said second patient comprises an ER alpha+ breast cancer cell, and wherein said Poly-Ig− receptor, or the (Fc) region thereof, is not detected in said sample from said second patient,
wherein said cancer patient sample comprises an ER alpha+ and Poly-Ig receptor+ breast cancer cell of mucosal origin.
2. The method of claim 1 , wherein the presence of the (Fc) region of the poly-Ig receptor in said cancer patient sample is indicative of said cancer patient being more susceptible to treatment with Tamoxifen.